Moderna's COVID-19 Vaccine mNEXSPIKE Gains FDA Approval
TL;DR
Moderna's new COVID-19 vaccine, mNEXSPIKE, has received FDA approval for use in adults 65+ and high-risk individuals aged 12-64, showing higher efficacy than its predecessor in clinical trials, with a similar safety profile, and is expected to be available in the US for the 2025-2026 season.
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE Moderna Investor RelationsView Full Coverage on Google News
Want the full story? Read the original reporting
Read on Moderna Investor Relations